Anand Subramony is Vice President of External innovation and Novel Technologies at AstraZeneca. In this role, Anand leads various cross functional teams and initiatives in the areas of nanomedicine, targeted therapy, new modalities, and digital technologies including sensors/diagnostics. His group is also responsible for the next generation FutureLab®, lab automation, and evaluating novel technologies.
Before his current role, Anand headed the drug delivery and device development at Medimmune. Prior to that, he was Principal Fellow and Head of the Novel Delivery Technologies & Therapeutics at the Novartis Institutes for BioMedical Research (NIBR, Cambridge, MA) where he established and managed a high performing cross functional team. In other roles, Dr. Subramony led the Materials Science function of the Biomedical Engineering group at Alza /J&J (Mountain View, CA), and was Director of Materials Science & Drug delivery at Dr. Reddy’s Laboratories (Bridgewater, NJ)
With his broad experience in pharma biotech, Dr. Subramony brings innovation and scientific rigor coupled with execution excellence and sense of urgency towards drug development to create patient centric products. Dr. Subramony holds an MS in Materials Sc. Engineering from IIT Bombay and PhD from Purdue University and was a research scientist at the University of Washington, Seattle before taking up industrial positions. He has several refereed publications and patents in the areas of drug delivery, nanomedicine, and devices.